This provides an advantage over direct acting GlyB antagonists which block NMDA-R channels throughout the body, or inhibitors of kynurenine 3-hydroxylase that will raise kynurenic acid levels globally in the brain, thereby making AV-101 a unique candidate for the management of LID in PD patients. The gene discussed is KMO; the disease is Parkinson disease.